LEXX — Lexaria Bioscience Share Price
Last trade - 00:00- $23.70m
- $16.78m
- $0.46m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.32 | ||
| Price to Tang. Book | 3.57 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 45.07 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -137.05% | ||
| Return on Equity | -172.37% | ||
| Operating Margin | -1786.29% | ||
Financial Summary
| Year End 31st Aug | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.31 | 0.72 | 0.26 | 0.23 | 0.46 | 0.59 | 0.79 | 15.84% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its primary research programs are the investigation of optimal formulations of DehydraTECH-enhanced glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drugs as well as the investigation of cannabidiol (CBD) for the reduction of hypertension leading to a cleared IND application by the United States Food and Drug Administration. It operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 46 patents granted and many patents pending worldwide.
Directors
- Christopher Bunka CHM (60)
- John Docherty PRE (51)
- Gregory Downey CFO (61)
- Nicholas Baxter IND (67)
- Ted McKechnie IND (73)
- Albert Reese IND (71)
- Last Annual
- August 31st, 2024
- Last Interim
- February 28th, 2025
- Incorporated
- December 9th, 2004
- Public Since
- October 28th, 2009
- No. of Shareholders
- 33
- No. of Employees
- 7
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 17,559,179
- Address
- 100 - 740 MCCURDY ROAD, KELOWNA, V1X 2P7
- Web
- https://www.lexariabioscience.com/
- Phone
- +1 2507656424
- Auditors
- Malone Bailey, LLP
Latest News for LEXX
Upcoming Events for LEXX
Q3 2025 Lexaria Bioscience Corp Earnings Release
Similar to LEXX
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
As of Today at 21:44 UTC, shares in Lexaria Bioscience are trading at $1.35. This share price information is delayed by 15 minutes.
Shares in Lexaria Bioscience last closed at $1.35 and the price had moved by -38.36% over the past 365 days. In terms of relative price strength the Lexaria Bioscience share price has underperformed the S&P500 Index by -43.1% over the past year.
The overall consensus recommendation for Lexaria Bioscience is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreLexaria Bioscience does not currently pay a dividend.
Lexaria Bioscience does not currently pay a dividend.
Lexaria Bioscience does not currently pay a dividend.
To buy shares in Lexaria Bioscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.35, shares in Lexaria Bioscience had a market capitalisation of $23.70m.
Here are the trading details for Lexaria Bioscience:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: LEXX
Based on an overall assessment of its quality, value and momentum Lexaria Bioscience is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Lexaria Bioscience is $7.50. That is 455.56% above the last closing price of $1.35.
Analysts covering Lexaria Bioscience currently have a consensus Earnings Per Share (EPS) forecast of -$0.59 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lexaria Bioscience. Over the past six months, its share price has underperformed the S&P500 Index by -46.31%.
As of the last closing price of $1.35, shares in Lexaria Bioscience were trading -42.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lexaria Bioscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lexaria Bioscience's management team is headed by:
- Christopher Bunka - CHM
- John Docherty - PRE
- Gregory Downey - CFO
- Nicholas Baxter - IND
- Ted McKechnie - IND
- Albert Reese - IND